EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prevalence of 3,4-Methylenedioxy-α-Pyrrolidinohexanophenone (3,4-MDPHP) in 465 Suspected Intoxication Cases and Cross-Reactivity Evaluation in an Ecstasy Immunoassay

Maurizio Pasi iD, Ilaria Giardini, Eleonora Buscaglia, Azzurra Schicchi, Carlo A Locatelli, Andrea Giampreti, Mariapina Gallo, Riccardo Albertini, Pietro Papa, Antonella Valli

The Journal of Applied Laboratory Medicine · 2026

DOI: 10.1093/jalm/jfaf165 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Applied Laboratory Medicine, 2026. Verfasst von Maurizio Pasi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio Ultraspecialistico di Patologia Clinica Farmacotossicologia e Sostanze d'abuso, Laboratorio Analisi Chimico Cliniche, Dipartimento di Med…. Hauptthemen laut MEDLINE: Substance Abuse Detection, Pyrrolidines, N-Methyl-3,4-methylenedioxyamphetamine, Psychotropic Drugs. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondazione IRCCS Policlinico San Matteo, Anti-Drug Policies Department, Presidency of the Council of Ministers.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The rise of synthetic cathinones (SC), and in particular 3,4-MDPHP (3,4-methylenedioxy-α-pyrrolidinohexanophenone), is a concerning health threat. This paper represents the most extensive case series on 3,4-MDPHP suspected intoxications to date, offering a detailed analysis of its impact.

Methods

This study presents the analytical findings for 108 hospitalized patients who tested positive for 3,4-MDPHP, out of a total of 465 subjects admitted for suspected new psychoactive substances (NPS) intoxication. Analyses were performed by GC-MS and LC-MS/MS. The potential cross-reactivity of 3,4-MDPHP with the Syva EMIT II Plus urine ecstasy immunoassay is also investigated.

Results

3,4-MDPHP was detected in 56% of NPS positive cases. A wide range of 3,4-MDPHP concentrations was observed in both blood (1–257 ng/mL) and urine (2–32 250 ng/mL). 3,4-MDPHP was the sole detected substance in 73.1% of cases, while 26.9% involved co-consumption with other drugs of abuse, primarily cocaine. Investigations about 3,4-MDPHP cross-reactivity with Syva EMIT II Plus urine ecstasy demonstrated that unmodified 3,4-MDPHP does not trigger a positive result, but its metabolites seem to be involved in a positive cross-reaction.

Conclusion

This study confirms the high prevalence (108/465) of 3,4-MDPHP in NPS related intoxication cases in our cohort. It is essential for clinical laboratories and emergency departments to be aware of the potential cross-reactivity in ecstasy immunoassay, as this may lead to significant diagnostic errors and misinterpretation of results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Substance Abuse DetectionPyrrolidinesN-Methyl-3,4-methylenedioxyamphetaminePsychotropic DrugsSubstance-Related DisordersHumansCross ReactionsImmunoassayMaleFemaleAdultGas Chromatography-Mass SpectrometryMiddle AgedTandem Mass SpectrometryYoung AdultChromatography, LiquidPrevalenceAdolescent

Substanzen

PyrrolidinesN-Methyl-3,4-methylenedioxyamphetaminePsychotropic Drugs

Autor:innen und Institutionen

  • Laboratorio Ultraspecialistico di Patologia Clinica Farmacotossicologia e Sostanze d'abuso, Laboratorio Analisi Chimico Cliniche, Dipartimento di Medicina Diagnostica e di Laboratorio, Fondazione IRCCS Policlinico San M…
  • U.O. Tossicologia, Centro Antiveleni di Pavia, Centro Nazionale di Informazione Tossicologica, Laboratori di Tossicologia Clinica e Sperimentale, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy.
  • Centro Antiveleni di Bergamo, ASST Papa Giovanni XXIII, Bergamo, Italy.

ORCID-Profile: Maurizio Pasi

Förderung

  • Fondazione IRCCS Policlinico San Matteo
  • Anti-Drug Policies Department
  • Presidency of the Council of Ministers
  • Instituti Clinici Scientifici Maugeri IRCCS Pavia

Zitieren

APA

Pasi, M., Giardini, I., Buscaglia, E., Schicchi, A., Locatelli, C. A., Giampreti, A., Gallo, M., Albertini, R., Papa, P., & Valli, A. (2026). Prevalence of 3,4-Methylenedioxy-α-Pyrrolidinohexanophenone (3,4-MDPHP) in 465 Suspected Intoxication Cases and Cross-Reactivity Evaluation in an Ecstasy Immunoassay. The Journal of Applied Laboratory Medicine. https://doi.org/10.1093/jalm/jfaf165

Vancouver

Pasi M, Giardini I, Buscaglia E, Schicchi A, Locatelli CA, Giampreti A, et al. Prevalence of 3,4-Methylenedioxy-α-Pyrrolidinohexanophenone (3,4-MDPHP) in 465 Suspected Intoxication Cases and Cross-Reactivity Evaluation in an Ecstasy Immunoassay. The Journal of Applied Laboratory Medicine. 2026. doi:10.1093/jalm/jfaf165

BibTeX
@article{Pasi2026,
  author = {Pasi, Maurizio and Giardini, Ilaria and Buscaglia, Eleonora and Schicchi, Azzurra and Locatelli, Carlo A and Giampreti, Andrea and Gallo, Mariapina and Albertini, Riccardo and Papa, Pietro and Valli, Antonella},
  title = {Prevalence of 3,4-Methylenedioxy-α-Pyrrolidinohexanophenone (3,4-MDPHP) in 465 Suspected Intoxication Cases and Cross-Reactivity Evaluation in an Ecstasy Immunoassay},
  journal = {The Journal of Applied Laboratory Medicine},
  year = {2026},
  doi = {10.1093/jalm/jfaf165}
}
Kostenlos starten →